References
- 1. Kang K, Polster AM, Nedorost ST, Stevens SR, Cooper KD. Atopic dermatitis. In: Bolognia JL, Jorizzo JJ. Dermatology. London: Elsevier; 2008.
- 2. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis): part I. J Eur Acad Dermatol Venereol 2012;26(8):1045-60.
- 3. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis): part II. J Eur Acad Dermatol Venereol 2012 ;26(9):1176-93.
- 4. Darsow U, Wollenberg A, Simon D, Taieb A, Werfel T, Oranje A, et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010;24(3):317-28.
- 5. Salek MS, Finlay AY, Luscombe DK, Allen BR, Berth-Jones J, Camp RD, et al. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 1993;129(4):422-30.
- 6. van Joost T, Heule F, Korstanje M, van den Broek MJ, Stenveld HJ, van Vloten WA. Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermatol 1994;130(5):634-40.
- 7. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980;92:44-7.
- 8. Czech W, Bräutigam M, Weidinger G, Schöpf E. A body-weightindependent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J Am Acad Dermatol 2000;42(4):653-9.
- 9. Harper JI, Ahmed I, Barclay G, Lacour M, Hoeger P, Cork MJ, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000;142(1):52-8.
- 10. Zurbriggen B, Wüthrich B, Cachelin AB, Wili PB, Kägi MK. Comparison of two formulations of cyclosporin A in the treatment of severe atopic dermatitis: a double-blind, singlecentre, cross-over pilot study. Dermatology 1999;198(1):56-60.
- 11. Zonneveld IM, De Rie MA, Beljaards RC, Van Der Rhee HJ, Wuite J, Zeegelaar J, et al. The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens. Br J Dermatol 1996;135(Suppl 48):15-20.
- 12. Pacor ML, Di Lorenzo G, Martinelli N, Mansueto P, Rini GB, Corrocher R. Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clin Exp Allergy 2004;34(4):639-45.
- 13. Haeck IM, Knol MJ, Ten Berge O, van Velsen SG, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol 2011;64(6):1074-84.
- 14. Kwakkel-van Erp JM, Haeck IM, Paantjens AW, van de Graaf EA, van Ginkel WG, Knol MJ, et al. Differential usefulness of biomarkers thymus and activation-regulated chemokine and soluble CD30 during enteric coated mycophenolate sodium and cyclosporine therapy in atopic dermatitis. J Am Acad Dermatol 2010;63(3):e70-2.
- 15. Schmitt J, Schäkel K, Fölster-Holst R, Bauer A, Oertel R, Augustin M, et al. Prednisolone vs. ciclosporin for severe adult eczema: an investigator-initiated double-blind placebocontrolled multicentre trial. Br J Dermatol 2010;162(3):661-8.
- 16 Arellano FM, Wentworth CE, Arana A, Fernandez C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007;127:808-16.
- 17. Hagstromer L, Ye W, Nyren O, Emstestam L. Incidence of cancer among patients with atopic dermatitis. Arch Dermatol 2005;141:1123-7.
- 18. Dinić M, Kandolf Sekulović L, Mladenović T, Zečević R. Erythrodermic cutaneous T-cell lymphomas: two case reports. Serb J Dermatol Venereol 2009;1(3):116-21, 19. Bos JD, Leent EJ, Sillevis-Smitt JH. The millennium criteria for the diagnosis of atopic dermatitis. Exp Dermatol 1998;7:132-8.